リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Pharmacokinetics and bioavailability of tildipirosin in goats using HPLC」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Pharmacokinetics and bioavailability of tildipirosin in goats using HPLC

Elazab, Sara Taha Abass, Marwa Elsaied 北海道大学

2020.02

概要

The goal of this study was to assess the pharmacokinetic properties of tildipirosin in female goats (n=15) following single intravenous (IV) injection at 4mg/kg and subcutaneous (SC) administration at 2 and 4 mg/kg. There were no adverse effects noted after IV and SC administration. Plasma concentrations of tildipirosin were measured using high-performance liquid chromatography (HPLC). The pharmacokinetic parameters of tildipirosin were computed by the non-compartmental model with WinNonlin 4.1 software. After single SC injection of 2 and 4 mg/kg, the maximum plasma concentrations were 571.6 ± 39.22 and 720 ± 52.99 ng/ml achieved at 30 min, respectively. Moreover, the mean values for the elimination half-life (T1/2λz) were 75.34 ± 2.71and 94.76 ± 8.13 hr, and the AUC0-last values were 11.09 ± 1.64 and 19.59 ± 4.18 respectively. The absolute bioavailability of tildipirosin after 4mg/kg SC injection was 96.64%. Tildipirosin was widely distributed following 4 mg/kg IV injection with volume of distribution 24.69 ± 4.10 L/kg and the plasma clearance was 0.216 ± 0.029 L/hr/kg. Tildipirosin showed favorable pharmacokinetic features in goats with rapid absorption, high bioavailability, wide distribution and long persistence in the body. These findings provide a guidance for using tildipirosin in goats.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1) Anonymous. Guideline on validation of bioanalytical methods. EMEA/CHMP/ EWP/192217/2009, 2009.

2) Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/ pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother 21, 319-329, 2015.

3) Boucher HW, Ambrose PG, Chambers H, Ebright RH, Jezek A, Murray BE, Newland JG, Ostrowsky B, Rex JH, America IDSo. White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. J Infect Dis 216, 228-236, 2017.

4) Chaffin MK, Cohen ND, Martens RJ. Chemoprophylactic effects of azithromycin against Rhodococcus equi–induced pneumonia among foals at equine breeding farms with endemic infections. J Am Vet Med Assoc 232, 1035-1047, 2008.

5) Drusano G, Louie A, Macgowan A, Hope W. Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 1. Antimicrob. Agents Chemother 60, 1183-1193, 2016.

6) EMA. European public MRL assesment Report (EPMAR): Tildipirosin (bovin, porcine and caprine species). EMA/CVMP/709377/2009, 2010.

7) EMA. CVMP assessment report Zuprevo (EMEA/V/C/002009) (last accessed 8 June, 2019), 2011.

8) Giguére S, Jacks S, Roberts GD, Hernandez J, Long MT, Ellis C. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia. J Vet Intern Med 18, 568-573, 2004.

9) Haddad N, Pedersoli W, Ravis W, Fazeli M, Carson JR. Combined pharmacokinetics of gen tami c in in pon y mar es after a single intravenous and intramuscular administration. Am J Vet Res 46, 2004-2007, 1985.

10) Huang R, Letendre L, Banav N, Fischer J, Somerville B. Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity. J Vet Pharmacol Ther 33, 227-237, 2010.

11) Lei Z, Liu Q, Yang B, Ahmed S, Cao J, He Q. The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis. Oncotarget 9, 1673, 2018.

12) Lombardi K, Portillo T, Hassfurther R, Hunter R. Pharmacokinetics of tilmicosin in beef cattle following intravenous and subcutaneous administration . J Vet Pharmacol Ther 34, 583-587, 2011.

13) Menge M, Rose M, Bohland C, Zschiesche E, Kilp S, Metz W, Allan M, Röpke R, Nürnberger M. Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle). J Vet Pharmacol Ther 35, 550-559, 2012.

14) Nowakowski MA, Inskeep PB, Risk JE, Skogerboe TL, Benchaoui HA, Meinert TR, Sherington J, Sunderland S. Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle. Veterinary therapeutics: research in applied veterinary medicine 5, 60-74, 2004.

15) Papich MG. Pharmacokinetic - pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs. Vet Microbiol 171, 480-486, 2014.

16) Rose M, Menge M, Bohland C, Zschiesche E, Wilhelm C, Kilp S, Metz W, Allan M, Röpke R, Nürnberger M. Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae. J Vet Pharmacol Ther 36, 140-153, 2013.

17) Schlünzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814, 2001.

18) Scott P, Mcgowan M, Sargison N, Penny C, Lowman B. Use of tilmicosin in a severe outbreak of respiratory disease in weaned beef calves. Aust Vet J 73, 62-64, 1996.

19) Torres F, Santamaria R, Jimenez M, Menjon R, Ibanez A, Collell M, Azlor O, Fraile L. Pharmacokinetics of tildipirosin in pig tonsils. J Vet Pharmacol Ther 39, 199-201, 2016.

20) Venner M, Kerth R, Klug E. Evaluation of tulathromycin in the treatment of pulmonary abscesses in foals. The Vet J 174, 418-421, 2007.

21) Wang J, Zhao T, Sun X, Liu Y, Zhu J, Zhang S, Cao X. Pharmacokinetics of tildipirosin in beagle dogs. J Vet Pharmacol Ther 41, e49-e52, 2018.

22) Zeng D, Sun M, Lin Z, Li M, Gehring R, Zeng Z. Pharmacokinetics and pharmacodynamics of tildipirosin against Pasteurella multocida in a murine lung infection model. Front in Microbiol 92018.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る